Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Shareholder Meeting (November 2017)
18 slides from Prescient Therapeutics's shareholder meeting presentation, Nov 20, 2017
Slide 1: AGM Overview 2017
For personal use only AGM OVERVIEW 2017 Prescient Therapeutics Limited (ASX: PTX) 20 November 2017
Slide 2: Disclaimer and Safe Harbor
DISCLAIMER AND SAFE HARBOR For personal use only Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts b
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS For personal use only 2 DRUGS » IMMINENT CATALYSTS » FUNDING IN PLACE » UNDISCOVERED VALUE • 2 targeted therapies with impeccable scientific pedigree • Multiple shots on goal with Akt and Ras pathway inhibitors in multiple trials • One of deepest clinical pipelines on the ASX »
Slide 4: Deep, Clinical Stage Product Pipeline
DEEP, CLINICAL STAGE PRODUCT PIPELINE For personal use only • PTX-200 currently in three clinical trials (BRCA recruitment currently on hold pending SAE response) • Advancing PTX-100 in rare haematological cancers – a transformative opportunity DISCOVERY SCREENING PRE-CLINICAL PHASE 1 PHASE 1B PHASE
Slide 5: How Our Drugs Work: A Refresh
HOW OUR DRUGS WORK: A REFRESH For personal use only Akt & Ras are growth molecules found in cells – when they are stuck “on”, they send constant signals to the cancer cell to grow PTX’s drugs block the Akt & Ras growth pathways, PTX-100 switching the growth signals off and causing the cancer cell to
Slide 6: Investment Decision Funnel for Any Biotech
INVESTMENT DECISION FUNNEL FOR ANY BIOTECH For personal use only Is the drug in a clinical trial, or still pre-clinical? Both drugs clinical stage Is the trial conducted to US FDA standard? All INDs (under US FDA) Do the indications make clinical & Targeting unmet/poorly met medical commercial
Slide 7: Last Year We Said
LAST YEAR WE SAID For personal use only • AML trial currently screening for first patient Ph1b • Ovarian cancer currently screening next patient Ph1b • Breast Cancer Ph1b expansion cohort nearing completion • Manufacturing new batch of PTX-200 • Interest in PTX-100 – planning development pro
Slide 8: The Year in Review
THE YEAR IN REVIEW For personal use only • Manufacturing run of PTX-200 • Commencement of PTX-200 Phase 1b AML trial • Successful completion of Phase 1b PTX-200 breast cancer trial • Subsequent SAE on patient on breast cancer trial leading to clinical hold on all PTX-200 trials • Progression of Phas
Slide 9: The PTX-200 Clinical Hold
THE PTX-200 CLINICAL HOLD For personal use only • After completion of the Phase 1b breast cancer trial, last patient passed away from liver failure • Hold on all 3 PTX-200 programs • Share price dropped 30% • Review on all data in PTX-200 trials • Enhanced safety measures include: » Excluding patien
Slide 10: Big Opportunity in Rare Hematological Niche
BIG OPPORTUNITY IN RARE HEMATOLOGICAL NICHE For personal use only • Recent discovery that RhoA mutations are a key driver in certain haematological cancers • Some of these conditions are characterized high unmet need: » Rare » Poor prognoses with short median survival » Very few existing treatment o
Slide 11: Ras Pathway and RhoA Implicated in Hematological Malignancies
RAS PATHWAY, AND RHOA IN PARTICULAR, ARE IMPLICATED IN A NUMBER OF HEMATOLOGICAL MALIGNANCIES For personal use only Frequency of RhoA mutations in human malignancies Indications of interest for PTX-100 • In addition, N-Ras and K-Ras contribute to several heme malignancies including: » Acute Myeloid
Slide 12: PTX-100 the Most Advanced Drug Targeting RhoA
PTX-100 THE MOST ADVANCED DRUG TARGETING RHOA • Only 12 RhoA inhibitors in development in For personal use only PTX-100 1 oncology » No others are in the clinic NO. OF DRUGS IN DEVELOPMENT » None are in hematology indications » PTX-100 is the most advanced, with Phase 1 7 trial in solid tumours comp
Slide 13: When Target Therapies Meet Rare Diseases: Loxo
WHEN TARGET THERAPIES MEET RARE DISEASES For personal use only Bayer agrees cancer drug deal with Loxo worth up to $1.55 bln November 14, 2017, 10:08:00 AM EDT By Reuters • Loxo Oncology (NASDAQ: LOXO); $2.3B market cap • TRK inhibitor targeting cancers with TRK fusions • Deal for LOXO-101 and LOXO-
Slide 14: When Target Therapies Meet Rare Diseases: Blueprint Medicines
WHEN TARGET THERAPIES MEET RARE DISEASES For personal use only • Blueprint Medicines (NASDAQ: BPMC) • Target therapies for cancer based on genomically defined diseases (abnormal kinase activation) • 4x Phase 1 drugs • 3 x discovery programs • IPO April 2015: Valuation: US$398M; $16/share • Today: Va
Slide 15: When Target Therapies Meet Rare Diseases: Prescient
WHEN TARGET THERAPIES MEET RARE DISEASES For personal use only • Prescient Therapeutics (ASX: PTX); market cap $14M • Target therapies for cancer • Hyper pAkt – PTX-200 » Orphan drug designation in AML • Ras pathway mutations – PTX-100 » Ultra-orphan RhoA mutant lymphomas • A step behind some US pee
Slide 16: In the Next Months We Will Work Towards
IN THE NEXT 12 MONTHS WE WILL WORK TOWARDS: For personal use only • Removal of clinical hold on PTX-200 breast cancer trial • Final data on the Phase 1b PTX-200 breast cancer trial • Manufacturing run of PTX-100 and additional inventory of PTX-200 • Pre-clinical work in PTX-100 in RhoA mutant cancer
Slide 17: Thank You
THANK YOU For personal use only …Thank you to our shareholders for their ongoing support …Thank you to our Board, staff and clinical faculty for working successfully though the challenges this year …Thank you to the brave patients we treat, and their families and support networks Together we are all
Slide 18: Thank You / Contact
For personal use only THANK YOU CONTACT Steven Yatomi-Clarke e: steven@ptxtherapeutics.com CEO & Managing Director t: +61 417 601 440 Prescient Therapeutics Limited w: ptxtherapeutics.com
Prescient Therapeutics — Shareholder Meeting (November 2017) on 6ix